If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.
Three or five years of adjuvant imatinib for the treatment of patients with operable GIST with a high risk of relapse: A randomized phase III study.
PURPOSE OF THE STUDY
Three years of imatinib is considered the standard duration of post therapy for patients with operable high-risk GIST. Yet, many patients are still at a high risk of GIST recurrence after completion of three years of adjuvant imatinib, and might benefit from further adjuvant imatinib therapy. The aim of SSGXXII is to compare the effect of giving imatinib for 5 years against 3 years, in patients who have undergone surgery for GIST, with the intent to prevent the tumour from coming back. The trial will look at the effect of the efficacy and safety of 5 years of treatment compared to 3 years.
DETAILED INFORMATION AVAILABLE
More detailed information to come.
Professor John Zalcberg, Chair
A/Prof Sumitra Ananda, Co-Chair
If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.